Drugs / CGP 77116
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00001781 | Feb 1998 → Mar 2002 | multiple sclerosis | National Institute of Neurological Disorders and Stroke (NINDS) | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CGP 77116 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00001781 ↗ |
| Action | Inhibit | “CGP 77116 may downregulate the MBP-specific immune response” NCT00001781 ↗ |
| Modality | Peptide | “CGP 77116 is an altered peptide ligand (APL)” NCT00001781 ↗ |
| Route | Other | “The drug will be given by injection” NCT00001781 ↗ |